Background: Our investigation aimed to visualize the 3-D spatial distribution of nasal cavity mucosal swelling under levocetirizine prophylactic treatment on exposure to allergens. This study made use of standard rhinologic diagnostics such as rhinomanometry and acoustic rhinometry, as well as 24 hours rhinometry and magnetic resonance imaging (MRI). Methods: A suitable test subject with a history of allergic rhinitis was identified during the symptom-free interval after the pollen season when she showed signs of "minimal persistent inflammation," consisting of pronounced reaction to nasal challenge with allergens. Provocation with birch pollen caused moderate symptoms of allergic rhinitis. Nasal provocation tests were performed before and after 2 and 5 weeks of treatment with levocetirizine 5 mg OD. Long-term rhinometry was carried out to detect the progress of the nasal cycle and relative flow variances over 24 hours. Flexible air tubes required for this new procedure made it possible to quantify relative pressure changes. High resolution MRI was also used to capture, visualize, and process the geometrical data of the nasal cavity immediately before and after the challenge tests. Based upon the MRI data, we computed the nasal airflow using a computational fluid dynamics (CFD) nasal model to visualize intranasal pressure and flow. Rhinomanometry and acoustic rhinometry were performed to validate the results. Results: After 36 days of treatment with levocetirizine, a 16% improvement in the nasal flow relative to baseline and an increase by 3.4 cm 3 of the total nasal baseline volume were documented as compared to the allergen challenge of the untreated case. 3-D images illustrated that treatment inhibited the allergen provocation effects on nasal airflow and normalised nasal flow velocity and pressure, including in the olfactory region. Conclusions: Besides improving the nasal airflow to an almost normal pattern, levocetirizine also helps prevents the patient from having an allergic response, even 24 hours after last drug intake. Furthermore, it can improve olfaction by restoring airflow to the olfactory region. Pharmacology, University of Medicine and Pharmacy, Cluj-Napoca, Romania. Background: Soluble intercellular adhesion molecule-1 (sICAM-1) and soluble vascular adhesion molecule-1 (sVCAM-1) play and important role in eosinophilic inflammation in allergic rhino-conjunctivitis (ARC). ICAM-1 and VCAM-1 have been identified as key molecules in allergic inflammatory diseases and in a few studies there was an increased value of those molecules in patients with allergic rhinitis. Treatment with H1 antihistamines is known to improve symptoms in allergic rhinitis and in vitro reduces the levels of adhesion molecules. Object: To evaluate serum levels of sICAM-1 and sVCAM-1 in pts with ARC to grass pollen and the response to different antihistamines. Methods: 50 pts with allergic rhino-conjunctivitis to grass pollen were evaluated regarding levels of sICAM-1 and sVCAM-1. The serum sICAM-1 and sVCAM-1 were evaluated during pollen season before and after antihistaminic terapy. Quantikine R&D System was used. Normal mean values in healthy volunteers were 208 ng/mL for sICAM and 557 ng/mL for sVCAM-1. 54% of pts were women and 88% from urban area. Results: Mean levels of sICAM-1 and sVCAM-1 were elevated before therapy of the pts compared with mean values in healthy subjects (235 ng/mL vs 208 ng/mL for sICAM and 966 ng/mL vs 557 ng/mL for sVCAM. 42% of pts received desloratadine therapy and 58% of them received levocetirizine. In both treated groups' levels of sICAM-1 and sVCAM-1 increased after one month of antihistaminic therapy but no statistical significance. Was obtained: in desloratadine group sICAM-1 (P ¼ 0.066) and sVCAM-1 (P ¼ 0.096); in levocetirizine group sICAM-1 (P ¼ 0.681) and sVCAM-1 (P ¼ 0.4060. Patients with high levels of sICAM-1 and sVCAM-1 at the tended to have increased sICAM-1 and sVCAM-1 levels at one month (P ¼ 0.000). No statistical difference was obtained between the 2 treated groups after one month regarding the levels of sICAM-1 and sVCAM-1. Conclusions: In patients with allergic rhino-conjunctivitis to grass pollen levels of sICAM-1 and sVCAM-1 are higher than in healthy subjects. Levels of sICAM-1 and sVCAM-1 in serum tend to increase during pollen season despite antihistaminic therapy.
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Methods:
We evaluated the effects of Fluticasone Furoate (FF) 110 mcg given in the morning on Nasal Symptons (NS), DS, an CP in adults with symptomatic SAR during an allergy season. 40 adults ages 18 to 55 with a history of SAR and positive allergy skin tests to seasonal allergens. After a 1 week placebo (PL) run in, they randomly received either FF (21) or identical appearing PL (19) for 2 weeks. They recorded nasal sympton score (NSS) and Eppworth daytime sleepiness score (EDDS) for the 21 days, performed a TOVA test (Computerized test of cognitive performance) at day 7 and 21, and completed a nocturnal rhinoconjunctivitis quality of life questionnaire (NRQLQ) at days 7, 14 and 21. Average daily weekly scores, comparing week 1 baseline to week 3 were used for evaluation of NSS, and EDSS/TOVA omissions, commissions and reaction times were compared, as was NRQLQ (day 7 and day 21). Results: Mean total NSS (TNSS) instantaneous decreased from BL 12.88 to 10.84 in the FF group, and increased in PL group from 12.64 to 13.74 (P diff ¼ .04). TNSS reflective decreased from 12.99 to 11.20 (FF group) and increased from 13.53 to 14.02 in PL. (P diff ¼ NS). The mean EDSS decreased from 13.83 to 10.76 (P ¼ 0.03) in FF group, and from 13.29 to 12.80 with PL (P dif ¼ NS). TOVA commissin errors decreased by 7.13 (FF) vs 1.4 (PL) (P dif ¼ 0.05). Omission increased in PL from 2.33 to 5.75, and 1.54 to 1.58 (FF) (P diff ¼ NS). Reaction time increased in both groups 363 to 391 milliseconds (FF), 387 to 412 milliseconds (P ¼ NS). The FF reported a minimally clinical importance difference of 0.5 or greater on all 16 questions of NRQLQ, the PL group only in 10. 2 Sanofi, Paris, France. Background: Allergic Rhinitis (AR) is a worldwide spread disease and has an important impact on social life, sleep quality (SQ), school and work productivity and huge direct costs. ISMAR was designed to identify attitudes and medical trends among physicians managing AR in different parts of the world. This study presents the physiciansview and attitudes.
